Market: NASD |
Currency: USD
Address: 1 Great Valley Parkway
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Show more
📈 TELA Bio, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$5.40
-
Upside/Downside from Analyst Target:
200.00%
-
Broker Call:
8
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
0-10%
-
Revenue Growth Range (1Y):
10-25%
-
Upcoming Earnings Date:
2025-11-07
-
EPS Estimate:
-0.20
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for TELA Bio, Inc.
Date | Reported EPS |
---|
2025-11-06 (estimated upcoming) | - |
2025-08-11 | -0.22 |
2025-05-08 | -0.25 |
2025-03-20 | -0.23 |
2024-11-07 | -0.42 |
2024-08-12 | -0.51 |
2024-05-10 | -0.54 |
2024-03-22 | -0.53 |
2023-11-09 | -0.45 |
2023-08-09 | -0.46 |
2023-05-11 | -0.63 |
2023-03-21 | -0.52 |
2022-11-09 | -0.64 |
2022-08-10 | -0.79 |
2022-05-10 | -0.75 |
2022-03-21 | -0.59 |
2021-11-10 | -0.57 |
2021-08-11 | -0.57 |
2021-05-13 | -0.56 |
2021-03-24 | -0.54 |
2020-11-11 | -0.53 |
2020-08-12 | -0.53 |
2020-05-12 | -0.63 |
2020-03-27 | -0.57 |
2019-12-18 | -0.59 |
📰 Related News & Research
No related articles found for "tela bio".